Stock ELEV ELEVATION ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
3.7 USD -3.14% Intraday chart for Elevation Oncology, Inc. +2.21% +589.01%
05-02 Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-05 Elevation Oncology, Inc. Announces Management Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
AQ
Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Elevation Oncology, Inc. Announces Management Changes
CI
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
MT
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
AQ
Wedbush Raises Elevation Oncology's PT to $8 From $5, Continues to See 'Intriguing' Opportunity in Shares; Keeps Outperform Rating
MT
Elevation Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors
CI
JMP Securities Starts Elevation Oncology' With Market Outperform Rating
MT
Elevation Oncology to Participate in Upcoming Investor Conferences
AQ
Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
PR
Elevation Oncology Expands Phase 1 Study of Potential Solid Tumor Treatment
MT
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
CI
HC Wainwright Adjusts Elevation Oncology Price Target to $6 From $1.50, Maintains Buy Rating
MT
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
AQ
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
AQ
Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee
CI
Latest Buzz on The Street: Noteworthy Developments at DYAI, ELEV, ATRA, ESPR, KAVL
AQ
Elevation Oncology Says It Has Funds to Continue Operations Into H2 2025
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELEV Stock
  4. News Elevation Oncology, Inc.